검색
검색 팝업 닫기

Ex) Article Title, Author, Keywords

Article

original article

Pharmacoepidemiology and Risk Management 2024; 16(2): 192-201

Published online September 30, 2024 https://doi.org/10.56142/perm.24.0018

Copyright © Korean Society for Pharmacoepidemiology and Risk Management.

Acid-Suppressive Therapy and Risk for C. difficile Infection: A Systematic Review and Meta-Analysis

위산분비억제제의 C. difficile 감염 위험에 관한 체계적 문헌고찰 및 메타분석

Dosol Oh, Kyu-Ri Kim, Seunghyun Cheon, Jee-Eun Chung

오도솔, 김규리, 천승현, 정지은

College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Korea

한양대학교 약학대학

Correspondence to:Jee-Eun Chung
College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-gu, Ansan 15588, Korea
Tel: +82-31-400-5816
Fax: +82-31-400-5989
E-mail: jechung@hanyang.ac.kr

Received: August 31, 2024; Revised: September 21, 2024; Accepted: September 23, 2024

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective: Acid-suppressive therapy is commonly used for stress ulcers; however, concerns have been raised regarding its potential to increase the risk of Clostridioides difficile infection (CDI). This study aimed to compare the risk of CDI associated with proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) among acid-suppressive agents. Methods: We conducted a meta-analysis to systematically evaluate the risk of CDI associated with PPIs compared to H2RAs. We searched 3 major databases up to April 30, 2024. The primary outcome was the incidence of CDI. Results: The meta-analysis of 14 articles involving 160,085 patients showed PPIs were associated with a 1.50-fold increase in the risk of CDI compared to H2RAs [95% CI: 1.22–1.85, I2 = 39%]. In a subgroup analysis of 8 out of 14 studies, which included 88,393 critically ill patients, PPIs were linked to a 1.58-fold increase in the risk of CDI compared to H2RAs [95% CI: 1.10–2.27, I2 = 61%]. In observational studies, PPIs were associated with a 1.55-fold increase in the risk of CDI [95% CI: 1.26–1.91, I2 = 33%]. In randomized trials, PPIs were not significantly associated with an increased risk of CDI compared to H2RAs [OR 1.92, 95% CI: 0.51–7.25, I2 = 41%]. Conclusion: Our findings indicate that PPIs are associated with a higher risk of CDI compared to H2RAs. Further well-controlled clinical trials are necessary to confirm these results.

KeywordsAcid-suppressive therapy, Proton Pump Inhibitors, Histamine H2 Antagonists, Clostridioides difficile

Korean Society for Pharmacoepidemiology and Risk Management

Vol.16 No.2
September, 2024

eISSN 2982-5954

Frequency: Bimonthly

Current Issue   |   Archives

Supplementary File

Stats or Metrics

Share this article on :

  • line